Given our earlier report of a correlation between poor prognosis and a lower CD8+ cell to Treg ratio in pre-treated esophageal cancer patients, Tregs in esophageal cancer, like in other solid tumors, may significantly impact immunotherapy efficacy by inhibiting the cytotoxic activity of CD8 associated with the tumor [43]. This evidence concerns the gene CD8A and neoplasm.